Generation of specific monoclonal antibodies against the extracellular loops of human claudin-3 by immunizing mice with target-expressing cells

Human claudin-3 (CLDN3) is a tetraspanin transmembrane protein of tight junction structures and is known to be over-expressed in some malignant tumors. Although a specific monoclonal antibody (MAb) against the extracellular domains of CLDN3 would be a valuable tool, generation of such MAbs has been regarded as difficult using traditional hybridoma techniques, because of the conserved sequence homology of CLDN3s among various species. In addition, high sequence similarity is shared among claudin family members, and potential cross-reactivity of MAb should be evaluated carefully. To overcome these difficulties, we generated CLDN3-expressing Chinese hamster ovary and Sf9 cells to use an immunogens and performed cell-based screening to eliminate cross-reactive antibodies. As a result, we generated MAbs that recognized the extracellular loops of CLDN3 but not those of CLDN4, 5, 6, or 9. Further in vitro studies suggested that the isolated MAbs possessed the desired binding properties for the detection or targeting of CLDN3. Graphical Abstract Epitope analysis revealed that the isolated MAbs recognized various extracellular domains of human CLDN3.

[1]  K. Yagi,et al.  Development of an Anti–Claudin-3 and -4 Bispecific Monoclonal Antibody for Cancer Diagnosis and Therapy , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[2]  J. Viola,et al.  Claudin-3 Overexpression Increases the Malignant Potential of Colorectal Cancer Cells: Roles of ERK1/2 and PI3K-Akt as Modulators of EGFR signaling , 2013, PloS one.

[3]  M. J. Kwon,et al.  Emerging Roles of Claudins in Human Cancer , 2013, International journal of molecular sciences.

[4]  A. Santin,et al.  Claudins Overexpression in Ovarian Cancer: Potential Targets for Clostridium Perfringens Enterotoxin (CPE) Based Diagnosis and Therapy , 2013, International journal of molecular sciences.

[5]  A. Yu,et al.  Claudins and the modulation of tight junction permeability. , 2013, Physiological reviews.

[6]  S. Howell,et al.  Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. , 2012, Neoplasia.

[7]  T. Tomita,et al.  Down-Regulation of Claudin-3 Is Associated with Proliferative Potential in Early Gastric Cancers , 2012, Digestive Diseases and Sciences.

[8]  K. Nakamura,et al.  Characterization and evaluation of the antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4. , 2010, Anticancer research.

[9]  Anton Hagenbeek,et al.  CD20-targeted therapy: the next generation of antibodies. , 2010, Seminars in hematology.

[10]  M. Cragg,et al.  CD20 as a target for therapeutic type I and II monoclonal antibodies. , 2010, Seminars in hematology.

[11]  H. Misaka,et al.  Therapeutic antitumor efficacy of monoclonal antibody against Claudin‐4 for pancreatic and ovarian cancers , 2009, Cancer science.

[12]  A. Santin,et al.  Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. , 2009, American journal of obstetrics and gynecology.

[13]  M. Sairam,et al.  Differential expression of claudin family proteins in mouse ovarian serous papillary epithelial adenoma in aging FSH receptor-deficient mutants. , 2006, Neoplasia.

[14]  M. Brännström,et al.  Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours , 2006, International journal of cancer.

[15]  P. Kufer,et al.  Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy , 2005, Cancer Immunology, Immunotherapy.

[16]  P. Parren,et al.  Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. , 2004, Blood.

[17]  K. Shitara,et al.  Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody. , 2000, Molecular immunology.

[18]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.